BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37799725)

  • 1. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.
    Shu Y; Xu W; Su R; Ran P; Liu L; Zhang Z; Zhao J; Chao Z; Fu G
    Front Immunol; 2023; 14():1251645. PubMed ID: 37799725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.
    Sun X; Song Z; Jiang H; Ma Y; Chen M
    Clin Imaging; 2022 Jun; 86():31-37. PubMed ID: 35325631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer.
    Qiu Q; Xing L; Wang Y; Feng A; Wen Q
    Front Immunol; 2022; 13():870842. PubMed ID: 35558076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.
    Barrón F; Sánchez R; Arroyo-Hernández M; Blanco C; Zatarain-Barrón ZL; Catalán R; Ramos-Ramírez M; Cardona AF; Flores-Estrada D; Arrieta O
    Front Oncol; 2020; 10():570233. PubMed ID: 33117699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
    Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
    Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
    Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
    Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images.
    Tan P; Huang W; Wang L; Deng G; Yuan Y; Qiu S; Ni D; Du S; Cheng J
    Front Physiol; 2022; 13():978222. PubMed ID: 35957985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Tohidinezhad F; Bontempi D; Zhang Z; Dingemans AM; Aerts J; Bootsma G; Vansteenkiste J; Hashemi S; Smit E; Gietema H; Aerts HJ; Dekker A; Hendriks LEL; Traverso A; De Ruysscher D
    Eur J Cancer; 2023 Apr; 183():142-151. PubMed ID: 36857819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
    Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
    Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
    Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
    Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
    Zhu L; Gao R; Li H; Zheng Y; Yang J
    Immunotherapy; 2024 Apr; 16(7):465-480. PubMed ID: 38511241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis.
    Li Y; Huang H; Ye X; Zeng B; Huang F; Chen L
    Medicine (Baltimore); 2024 Apr; 103(16):e37808. PubMed ID: 38640289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
    Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
    Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease.
    Allen E; Umoru G; Ajewole V; Bernicker E
    Front Oncol; 2023; 13():1283360. PubMed ID: 37941544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.
    Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
    Transl Lung Cancer Res; 2022 Sep; 11(9):1835-1846. PubMed ID: 36248332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.